Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique

#81 Type 2 Diabetes and A1c targets: Pragmatic dogma

What are reasonable Hemoglobin A1c (A1c) targets for our patients with Type 2 Diabetes Mellitus?

While many patients can safely attain an A1c at or just below 7%, older patients, those with long-standing diabetes, multiple co-morbidities, and/or high risk of hypoglycemia, reasonable targets are perhaps 7-8% or even higher.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

Intense management of blood glucose in Type 2 Diabetes examined in ≥ ten meta-analyses. 1-10
  • Studies varied in ages, co-morbidities, medications, etc., making evidence interpretation and application more difficult.
Five reasonably sized trials fall into two groups:
  • Newly diagnosed diabetics, age ~50’s, few co-morbidities, receiving single glucose lowering therapy (to start) versus diet.
    • UKPDS 33: 3,867 patients, sulfonylurea or insulin (median ten year A1c 7.0% versus 7.9%).11
      • Over ten years, significant reduction in death Number Needed to Treat (NNT)=29 and myocardial infarction (MI) NNT=36. 12
    • UKPDS 34: 753 patients, metformin (median ten year A1c 7.4% versus 8.0%). 13
      • Over ten years, significant reduction in death NNT=14 and MI NNT=16. 12
  • Older, established diabetics, age ~60’s, more co-morbidities, receiving multiple glucose-lowering therapies (to start) for intense versus conventional.
    • ACCORD:14 10,251 patients, x3.5 years, AIC 6.4% versus 7.5%.
    • ADVANCE:15 11,140 patients, x5 years, A1C 6.5% versus 7.3%.
    • Veterans:16 1,791 patients, x5.6 years, A1C 6.9% versus 8.4%.
    • Intense management led to:
      • Microvascular improvement:17 Prevented visual deterioration (three lines worse on Snellen chart) NNT=60 and loss of light touch sensation NNT=49.
      • No benefit in cardiovascular outcomes14-16 except one study found reduced non-fatal MI NNT=100. 15
      • Inconsistently worse: mortality in one study14 Number Needed to Harm (NNH)=96 and hospitalization in another15 NNH=48.
      • Consistently worse:14-16 Weight gain (gain ≥10kg14 NNH=8), and hypoglycemia (severe requiring medical assistance NNH=15).
  • New US-European Guidelines18 recommend less stringent targets in patients with longer disease duration, shorter life expectancy, increased co-morbidities, and high risk of hypoglycemia or other adverse events.
  • Cohort data indicates that in established diabetics, A1c of 7.5% may have the lowest mortality.19
  • Macrovascular complications such as cardiovascular events are much more common than end-stage microvascular endpoints such as progression to dialysis or blindness.11,20

Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • G. Michael Allan MD CCFP
  • Jacques Romney MD FRCPC

1. Tkác I. Diabetes Res Clin Pract. 2009; 86 Suppl 1:S57-62.

2. Marso SP, Kennedy KF, House JA, et al. Diab Vasc Dis Res. 2010; 7:119-30.

3. Ray KK, Seshasai SR, Wijesuriya S, et al. Lancet. 2009; 373:1765-72.

4. Hemmingsen B, Lund SS, Gluud C, et al. BMJ. 2011; 343:d6898.

5. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. BMJ. 2011; 343:d4169.

6. Zhang CY, Sun AJ, Zhang SN, et al. Ann Med. 2010; 42:305-15.

7. Macisaac RJ, Jerums G. Heart Lung Circ. 2011; 20:647-54.

8. Kelly TN, Bazzano LA, Fonseca VA, et al. Ann Intern Med. 2009; 151:394-403.

9. Mannucci E, Monami M, Lamanna C, et al. Nutr Metab Cardiovasc Dis. 2009; 19:604- 12.

10. Turnbull FM, Abraira C, Anderson RJ, et al. Diabetologia. 2009; 52:2288-98.

11. UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837–53.

12. Holman RR, Paul SK, Bethel MA, et al. N Engl J Med. 2008; 359:1577-89.

13. UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352:854–65.

14. Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD). N Engl J Med. 2008; 358:2545-59.

15. ADVANCE Collaborative Group. N Engl J Med. 2008; 358:2560-72.

16. Duckworth W, Abraira C, Moritz T, et al. N Engl J Med. 2009; 360:129-39.

17. Smail-Beigi F, Craven T, Banerji MA, et al. Lancet. 2010; 376:419-30.

18. Inzucchi SE, Bergenstal RM, Buse JB, et al. Diabetes Care. 2012; 35:1364-79.

19. Currie CJ, Peters JR, Tynan A, et al. Lancet. 2010; 375:481-9.

20. Bruno G, Biggeri A, Merletti F, et al. Diabetes Care. 2003; 26:2353-8.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 05/08/2016

By: Ricky D. Turgeon BSc(Pharm) ACPR PharmD


Evidence Updated: No new evidence; Bottom Line: No change.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks